GRAIG SANDERS: Open Payments
NPI 1932177912 · NEW HAVEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,936 in 107 payments from 16 companies in 2025. Trend: 2023 $1,590 · 2024 $1,793 · 2025 $1,936
Food & beverage: $1,936
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 42 | $514 |
| Novartis Pharmaceuticals Corporation | 14 | $230 |
| Amgen Inc. | 9 | $190 |
| AstraZeneca Pharmaceuticals LP | 8 | $157 |
| Merck Sharp & Dohme LLC | 6 | $142 |
| Esperion Therapeutics, Inc. | 5 | $134 |
| Novo Nordisk Inc | 4 | $110 |
| Actelion Pharmaceuticals US, Inc. | 4 | $106 |
| Alnylam Pharmaceuticals Inc. | 4 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $83 |
Products named: CAMZYOS, LEQVIO, Repatha, NEXLETOL, ELIQUIS, VERQUVO, Wegovy, OPSUMIT.
Industry payments across CT — which companies pay providers there.
